Whanin Pharm Co Ltd
KRX:016580
Intrinsic Value
Whan In Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical supplies. [ Read More ]
The intrinsic value of one Whanin Pharm Co Ltd stock under the Base Case scenario is 14 361.41 KRW. Compared to the current market price of 14 460 KRW, Whanin Pharm Co Ltd is Overvalued by 1%.
Valuation Backtest
Whanin Pharm Co Ltd
Run backtest to discover the historical profit from buying and selling Whanin Pharm Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Whanin Pharm Co Ltd
| Current Assets | 212.1B |
| Cash & Short-Term Investments | 78.1B |
| Receivables | 78.9B |
| Other Current Assets | 55.1B |
| Non-Current Assets | 189.1B |
| Long-Term Investments | 52.2B |
| PP&E | 131.2B |
| Intangibles | 5.4B |
| Other Non-Current Assets | 300.8m |
| Current Liabilities | 40B |
| Accounts Payable | 18.1B |
| Accrued Liabilities | 4.9B |
| Other Current Liabilities | 17B |
| Non-Current Liabilities | 3B |
| Long-Term Debt | 307.1m |
| Other Non-Current Liabilities | 2.7B |
Earnings Waterfall
Whanin Pharm Co Ltd
|
Revenue
|
230.4B
KRW
|
|
Cost of Revenue
|
-131.2B
KRW
|
|
Gross Profit
|
99.2B
KRW
|
|
Operating Expenses
|
-69B
KRW
|
|
Operating Income
|
30.2B
KRW
|
|
Other Expenses
|
-396m
KRW
|
|
Net Income
|
29.8B
KRW
|
Free Cash Flow Analysis
Whanin Pharm Co Ltd
Profitability Score
Profitability Due Diligence
Whanin Pharm Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Whanin Pharm Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Whanin Pharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Whanin Pharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Whanin Pharm Co Ltd
According to Wall Street analysts, the average 1-year price target for Whanin Pharm Co Ltd is 21 420 KRW with a low forecast of 21 210 KRW and a high forecast of 22 050 KRW.
Shareholder Return
Price
Whanin Pharm Co Ltd
| Average Annual Return | 0.41% |
| Standard Deviation of Annual Returns | 11.5% |
| Max Drawdown | -45% |
| Market Capitalization | 220.8B KRW |
| Shares Outstanding | 15 267 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Whan In Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical supplies. The company is headquartered in Seoul, Seoul. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company’s products consist of antidepressants, antipsychotics, anxiolytics, hypnotics, antiepileptics, attention-deficit/hyperactivity disorder (ADHD) agents, nootropics, antiparkinson drugs, anti-dementia drugs, gastrointestinal drugs, cardiovascular drugs, immunostimulating agents, antibiotics, multi-vitamins, respiratory drugs, dermatologic drugs, antivirals, anti-diabetic agents and others. The firm also involves in the real estate rental business.
Contact
IPO
Employees
Officers
The intrinsic value of one Whanin Pharm Co Ltd stock under the Base Case scenario is 14 361.41 KRW.
Compared to the current market price of 14 460 KRW, Whanin Pharm Co Ltd is Overvalued by 1%.
You don't have any saved screeners yet
